FluxMPS™ RPMI 1640 Medium with 25mM HEPES w/o L-Glutamine, Sodium Pyruvate, Phenol Red: 1X Liquid

FluxMPS™ RPMI 1640 Medium with 25mM HEPES — w/o L-Glutamine, Sodium Pyruvate, Phenol Red (1X Liquid)

FluxMPS™ DCP-RPMIH-QPR1X is a Microfluidics Suitable, quadruple-stage ultra-filtered RPMI 1640 + 25mM HEPES formulation engineered for hematopoietic cells, lymphocytes and related immune-cell models on organ-on-a-chip (OoC) and microphysiological system (MPS) platforms. Processed through a quadruple-stage filtration train (0.1 µm ×2 + 0.04 µm ×2) reaching a 0.04 µm final cut-off — five times finer than the 0.22 µm membranes used for conventional sterile filtration. HEPES (25 mM, pKa 7.3 at 37°C) provides robust pH buffering alongside sodium bicarbonate. Formulation: [+] Sodium Bicarbonate, [+] HEPES (25 mM), [+] Calcium, [+] Magnesium, [+] Glucose (2.0 g/L) | [-] L-Glutamine, [-] Phenol Red, [-] Sodium Pyruvate.

• Glucose retained at 2000 mg/L (2.0 g/L) for full glycolytic support of hematopoietic and immune cell cultures
• Dual buffering: 25 mM HEPES (pKa 7.3 at 37°C) plus 2000 mg/L sodium bicarbonate for pH stability in and out of the CO₂ incubator
• L-Glutamine, sodium pyruvate and phenol red intentionally excluded — add glutamine/GlutaMAX or pyruvate to match your protocol; the phenol-red-free base supports autofluorescence-sensitive imaging and flow cytometry
• Reduced glutathione (1.0 mg/L) included for redox/antioxidant support in lymphocyte and hematopoietic cultures
• Quadruple-stage filtration train (0.1 µm ×2 + 0.04 µm ×2), a 0.04 µm final pore size — five times finer than 0.22 µm conventional filtration
• Endotoxin release specification < 0.05 EU/mL (LAL, USP <85>) to reduce the risk of TLR4-driven artefacts in immune cell assays
• Manufactured under an ISO 13485:2016 quality management system with a per-lot Certificate of Analysis
• Ultrapure Type 1 water (18.2 MΩ·cm) used throughout formulation and aseptic fill

Engineered where standard media fails

Conventional 0.22 µm–filtered RPMI passes mycoplasma-sized particles, subvisible particulates, and endotoxin fragments that can activate TLR4 and confound immune cell assays. FluxMPS™ is built to address these failure modes.

Quadruple-stage filtration system

Four serial filtration stages — two dedicated 0.1 µm/0.04 µm prefilter-and-final-filter pairs run in series — reach a final 0.04 µm polish under aseptic fill conditions.

1. 1

   0.1 µm Prefiltration I

   Removes large particulates, cell debris and protein aggregates; protects the first 0.04 µm cartridge.

2. 2

   0.04 µm Final filtration I

   First 0.04 µm pass; retains sub-micron particulates and microaggregates that pass a 0.22 µm filter.

3. 3

   0.1 µm Prefiltration II

   Second dedicated prefilter, protecting the second 0.04 µm cartridge.

4. 4

   0.04 µm Final filtration II — Polish

   Ultimate polishing filter ahead of aseptic fill and finish.

Immune cell OoC and hematopoietic applications

FluxMPS™ DCP-RPMIH-QPR1X — RPMI 1640 + 25mM HEPES — delivers 0.04 µm filtered, Microfluidics Suitable media for hematopoietic cells and related OoC applications.

Automated Bioreactors & Robotics

An optional 0.01 µm (10 nm) ultra nano-filtered MPS Grade variant of this formulation is available on request for automated perfusion and robotic handling systems.

• Total Particulate Exclusion: 10 nm filtration removes nanoparticulate aggregates
• Valve & Sensor Protection: Reduces micro-fouling risk in automated perfusion systems
• Extended Perfusion Stability: Consistent nutrient delivery over long-duration culture

Inquiry Required: Contact support@diagnocine.com for the 0.01 µm MPS Grade variant.

Analytical release specifications

Every batch released against the full specification matrix below. Available pack sizes: 500 mL, 1000 mL. Certificate of Analysis: support@diagnocine.com.

Full composition (mg/L)

RPMI 1640 + 25mM HEPES: 39 ingredients per lot, with CAS numbers for raw-material traceability where known. RPMI 1640 contributes reduced glutathione (antioxidant) and a balanced amino acid/vitamin profile suited to lymphocyte and hematopoietic cell culture.

Manufacturing & compliance

Every FluxMPS™ product is manufactured and released under a multi-layer quality system.

How DCP-RPMIH-QPR1X compares

FluxMPS™ DCP-RPMIH-QPR1X vs. conventional 0.22 µm–filtered RPMI formulations.

Comparison figures from published supplier specifications, accessed 2026-09-02. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".

Frequently asked questions

Common questions about FluxMPS™ DCP-RPMIH-QPR1X — RPMI 1640 + 25mM HEPES.

Supporting literature

Key publications supporting RPMI 1640 + 25mM HEPES in immune cell culture and OoC applications.

1. Moore GE, et al. Culture of normal human leukocytes. JAMA. 1967;199:519–524. doi:10.1001/jama.1967.03120080053007
2. Huh D, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328:1662–1668. doi:10.1126/science.1188302
3. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32:760–772. doi:10.1038/nbt.2989
4. Novak R, et al. Robotic fluidic coupling and interrogation of multiple vascularized organ chips. Nat Biomed Eng. 2020;4:407–420. doi:10.1038/s41551-019-0497-x
5. Jang KJ, et al. Human kidney proximal tubule-on-a-chip. Integr Biol. 2013;5:1119–1129. doi:10.1039/c3ib40049b
6. Schimek K, et al. Integrating biological vasculature into a multi-organ-chip microsystem. Lab Chip. 2013;13:3588–3598. doi:10.1039/c3lc50217a
7. Luni C, et al. High-efficiency cellular reprogramming with microfluidics. Nat Methods. 2016;13:446–452. doi:10.1038/nmeth.3832
8. Sung JH, et al. Microfabricated mammalian organ systems. Lab Chip. 2013;13:1201–1212. doi:10.1039/c3lc41017j